Provided by Tiger Trade Technology Pte. Ltd.

Terns Pharmaceuticals, Inc.

53.17
+0.31000.59%
Post-market: 53.170.00000.00%18:05 EDT
Volume:19.69M
Turnover:1.04B
Market Cap:5.80B
PE:-51.53
High:53.19
Open:52.84
Low:52.78
Close:52.86
52wk High:53.19
52wk Low:1.87
Shares:109.00M
Float Shares:80.32M
Volume Ratio:1.03
T/O Rate:24.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0319
EPS(LYR):-1.1175
ROE:-29.12%
ROA:-19.94%
PB:20.40
PE(LYR):-47.58

Loading ...

Merck to acquire Terns Pharmaceuticals for $53.00 per share in cash, or $6.7B

TIPRANKS
·
Mar 25

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

GlobeNewswire
·
Mar 25

Merck & Co Inc - Deal Approved by Both Boards; Closing Subject to Majority of Terns Stockholders Tendering Shares

THOMSON REUTERS
·
Mar 25

Deals of the day-Mergers and acquisitions

Reuters
·
Mar 25

Terns Pharmaceuticals Shares up 14.1% Premarket After FT Reports Merck Nears $6 Bln Acquisition of Co

THOMSON REUTERS
·
Mar 25

Merck Nears Acquisition of Terns Pharmaceuticals to Strengthen Blood Cancer Treatment Portfolio

Stock News
·
Mar 25

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

Reuters
·
Mar 25

Talks Between Merck and Terns Were at an Advanced Stage and Deal Could Be Reached in Coming Days - FT

THOMSON REUTERS
·
Mar 25

Merck's All-Cash Deal Is Expected to Value Terns at Roughly $6Bn - FT

THOMSON REUTERS
·
Mar 25

U.S. Earnings Preview: After Market Close March 18

Dow Jones
·
Mar 19

Terns Pharmaceuticals CEO Amy L. Burroughs disposes of USD 681,073 in common shares

Reuters
·
Mar 18

Unusually active option classes on open March 13th

TIPRANKS
·
Mar 13

Terns Pharmaceuticals publishes corporate presentation on TERN-701 oral allosteric BCR-ABL inhibitor for CML with 75% MMR at 24 weeks

Reuters
·
Mar 10

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

GlobeNewswire
·
Feb 26

Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential

TIPRANKS
·
Feb 19

Terns Pharmaceuticals CEO Amy L. Burroughs Disposes of Common Shares

Reuters
·
Feb 19

Leerink Partners Initiates Coverage on Terns Pharmaceuticals With Outperform Rating, $58 Price Target

MT Newswires Live
·
Feb 09

Terns Pharmaceuticals initiated with an Outperform at Leerink

TIPRANKS
·
Feb 09

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)

TIPRANKS
·
Feb 05

A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update

Simply Wall St.
·
Feb 04